Fremanezumab

Phase 3

Teva Pharmaceutical Industries Limited (TEVA)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

6 competitors in Migraine

AXSMAXS-07 (MoSEIC meloxicam and rizatriptan)

Phase 3

AXSMAXS-07 (meloxicam-rizatriptan)

Phase 3

View Full Landscape

Drug Information

Target Indication

Migraine

Clinical Trial

NCT05458011

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA3/28/2019

Ajovy

Ajovy is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

TEVA

Teva Pharmaceutical Industries Limited

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

rasagiline mesylate 1.0 mgPhase 3

Parkinson's Disease

1.0 mg rasagiline mesylatePhase 3

Parkinson's Disease

BDPPhase 3

Allergic Rhinitis

TEV-56248Phase 3

Asthma

Non-Oral Corticosteroid (non-OCS) Asthma MedicationPhase 3

Asthma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts